Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Oakland
1955
mi
from 91732
Pontiac, MI
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Oakland
1955
mi
from 91732
Pontiac, MI
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Lake Huron Medical Center
2002
mi
from 91732
Port Huron, MI
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Lake Huron Medical Center
2002
mi
from 91732
Port Huron, MI
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford Clinic North-Bemidgi
1513
mi
from 91732
Bemidji, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford Clinic North-Bemidgi
1513
mi
from 91732
Bemidji, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Essentia Health Cancer Center
1610
mi
from 91732
Duluth, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Essentia Health Cancer Center
1610
mi
from 91732
Duluth, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Essentia Health Saint Mary's Medical Center
1609
mi
from 91732
Duluth, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Essentia Health Saint Mary's Medical Center
1609
mi
from 91732
Duluth, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Etzell, Paul S MD (UIA Investigator)
1424
mi
from 91732
Fergus Falls, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Etzell, Paul S MD (UIA Investigator)
1424
mi
from 91732
Fergus Falls, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Swenson, Wade II, MD (UIA Investigator)
1424
mi
from 91732
Fergus Falls, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Swenson, Wade II, MD (UIA Investigator)
1424
mi
from 91732
Fergus Falls, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Meeker County Memorial Hospital
1456
mi
from 91732
Litchfield, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Meeker County Memorial Hospital
1456
mi
from 91732
Litchfield, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology PA-Maplewood
1521
mi
from 91732
Maplewood, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology PA-Maplewood
1521
mi
from 91732
Maplewood, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
1510
mi
from 91732
Minneapolis, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
1510
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Minnesota Cooperative Group Outreach Program
1510
mi
from 91732
Minneapolis, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Minnesota Cooperative Group Outreach Program
1510
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Virginia Piper Cancer Institute
1508
mi
from 91732
Minneapolis, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Virginia Piper Cancer Institute
1508
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
1511
mi
from 91732
Minneapolis, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
1524
mi
from 91732
Rochester, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Coborn Cancer Center at Saint Cloud Hospital
1484
mi
from 91732
Saint Cloud, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Coborn Cancer Center at Saint Cloud Hospital
1484
mi
from 91732
Saint Cloud, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota Community Oncology Research Consortium
1505
mi
from 91732
Saint Louis Park, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota Community Oncology Research Consortium
1505
mi
from 91732
Saint Louis Park, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Regions Hospital
1517
mi
from 91732
Saint Paul, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Regions Hospital
1517
mi
from 91732
Saint Paul, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Joseph's Hospital - Healtheast
mi
from 91732
Saint Paul, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Joseph's Hospital - Healtheast
mi
from 91732
Saint Paul, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology PA-Woodbury
1522
mi
from 91732
Woodbury, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology PA-Woodbury
1522
mi
from 91732
Woodbury, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Woodwinds Health Campus
1521
mi
from 91732
Woodbury, MN
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Woodwinds Health Campus
1521
mi
from 91732
Woodbury, MN
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Nebraska Cancer Research Center
1258
mi
from 91732
Lincoln, NE
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Nebraska Cancer Research Center
1258
mi
from 91732
Lincoln, NE
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Missouri Valley Cancer Consortium
1300
mi
from 91732
Omaha, NE
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Missouri Valley Cancer Consortium
1300
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Alegent Health Immanuel Medical Center
1297
mi
from 91732
Omaha, NE
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Alegent Health Immanuel Medical Center
1297
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
2122
mi
from 91732
Winston-Salem, NC
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
2122
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford Bismarck Medical Center
1257
mi
from 91732
Bismarck, ND
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford Bismarck Medical Center
1257
mi
from 91732
Bismarck, ND
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford Broadway Medical Center
1416
mi
from 91732
Fargo, ND
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford Broadway Medical Center
1416
mi
from 91732
Fargo, ND
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford Clinic North-Fargo
1415
mi
from 91732
Fargo, ND
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford Clinic North-Fargo
1415
mi
from 91732
Fargo, ND
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital-Cedar Crest
2354
mi
from 91732
Allentown, PA
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital-Cedar Crest
2354
mi
from 91732
Allentown, PA
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center-Cancer Center Hazleton
2329
mi
from 91732
Hazleton, PA
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center-Cancer Center Hazleton
2329
mi
from 91732
Hazleton, PA
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Geisinger Wyoming Valley/Henry Cancer Center
2337
mi
from 91732
Wilkes-Barre, PA
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Geisinger Wyoming Valley/Henry Cancer Center
2337
mi
from 91732
Wilkes-Barre, PA
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Spartanburg Medical Center
2040
mi
from 91732
Spartanburg, SC
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Spartanburg Medical Center
2040
mi
from 91732
Spartanburg, SC
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford Cancer Center-Oncology Clinic
1313
mi
from 91732
Sioux Falls, SD
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford Cancer Center-Oncology Clinic
1313
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Medical X-Ray Center, PC
1313
mi
from 91732
Sioux Falls, SD
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Medical X-Ray Center, PC
1313
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sanford USD Medical Center - Sioux Falls
1313
mi
from 91732
Sioux Falls, SD
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sanford USD Medical Center - Sioux Falls
1313
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Virginia Cancer Center
2207
mi
from 91732
Charlottesville, VA
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Virginia Cancer Center
2207
mi
from 91732
Charlottesville, VA
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
2269
mi
from 91732
Richmond, VA
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Medical Center
961
mi
from 91732
Seattle, WA
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Medical Center
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
1745
mi
from 91732
Green Bay, WI
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
1745
mi
from 91732
Green Bay, WI
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Saint Mary's
1743
mi
from 91732
Green Bay, WI
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Saint Mary's
1743
mi
from 91732
Green Bay, WI
Click here to add this to my saved trials
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
HSHS Saint Nicholas Hospital
1746
mi
from 91732
Sheboygan, WI
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
HSHS Saint Nicholas Hospital
1746
mi
from 91732
Sheboygan, WI
Click here to add this to my saved trials
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
25
mi
from 91732
Los Angeles, CA
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
356
mi
from 91732
San Francisco, CA
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
1654
mi
from 91732
Madison, WI
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
1785
mi
from 91732
Birmingham, AL
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate
Status: Enrolling
Updated:  12/31/1969
Phoenix Children's Hospital
345
mi
from 91732
Phoenix, AZ
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate
Status: Enrolling
Updated: 12/31/1969
Phoenix Children's Hospital
345
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials